Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: Results of a phase II study

Clinical Lymphoma

Volumn 4, Issue 2, 2003, Pages 93-98

  Gregory, Stephanie A ^a   Case Jr , Delvyn C ^b   Bosserman, Linda ^c   Litwak, Debra L ^d   Berry, William R ^e   Kalman, Leonard A ^f   Belt, Robert J ^g   Saven, Alan ^h  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c Wilshire Oncology Group   (United States)

^d AMGEN INC   (United States)

^e Rex Cancer Center   (United States)

^f Oncology Hematology Group of South Florida   (United States)

^g Kansas City Cancer Center   (United States)

^h SCRIPPS CLINIC   (United States)

Author keywords

Chemotherapy; Dose escalation; Dose intensity; Hematologic toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PROPHYLAXIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0142217443     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.017     Document Type: Article

References (24)

1. Fisher RI. Diffuse large-cell lymphoma. Ann Oncol 2000; 11 (suppl 1):29-33.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
3. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990; 66:1124-1129.
4. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8:963-977.
5. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993; 4:651-656.
6. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24(4 suppl 10):S10-3-S10-10.
7. Pronzato P, Lionetto R, Botto F, et al. High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study. Br J Cancer 1998; 78:777-780.
8. Smith GM, Child JA, Cullen MH, et al. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group. Hematol Oncol 1996; 14:193-201.
9. Pfreundschuh M, Trumper L, Kloess M, et al. 2-Weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Blood 2001; 98:725a (Abstract #3027).
10. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
11. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38:1484-1493.
12. Gordon LI, Young M, Weller E, et al. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood 1999; 94:3307-3314.
13. Wolf M, Matthews J, Stone J, et al. Dose-Intensification does not improve outcome in aggressive non-Hodgkin's lymphoma (NHL). Report of a randomized trial by the Australasian Leukemia and Lymphoma Group (ALLG). Blood 2000; 96:832a (Abstract #3593).
14. Shipp MA, Neuberg D, Janicek M, et al. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13:2916-2923.
15. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999; 17:93-100.
16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
17. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88:2398-2424.
18. Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998; 9:1219-1227.
19. Zelenetz AD, Reider PA, Delgado DJ. Review of patterns of care among community physicians in intermediate grade NHL (IGL) reveals significantly greater planned and delivered dose attenuation in older patients. Blood 2000; 96:137a (Abstract #588).
20. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2:47-56.
21. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4:295-305.
22. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33-38.
23. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430-1436.
24. Pfreundschuh M, Truemper L, Kloess M, et al. 2-weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-B-2 trial of the DSHNHL. Blood 2002; 100:774a (Abstract #3060).